The purpose of this study is to demonstrate that AZD3480 improves cognition in patients with stable schizophrenia who are being treated with an atypical antipsychotic and who are active cigarette smokers, to assess the safety and tolerability of AZD3480 and to define the optimal dose(s) to be used in future trials.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
400
oral capsule
Domain scores for Attention/Vigilance, Working Memory, Verbal Learning, Speed of Processing and Verbal Fluency as measured on the IntegNeuro computerized test battery of cognitive function
Time frame: Change from baseline to Week 12
UCSD Performance Based Skills Assessment (UPSA2) and on the Social Functioning Scale (SFS)
Time frame: Change from baseline to Week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Research Site
Little Rock, Arkansas, United States
Research Site
Anaheim, California, United States
Research Site
Cerritos, California, United States
Research Site
Costa Mesa, California, United States
Research Site
Escondido, California, United States
Research Site
Garden Grove, California, United States
Research Site
Long Beach, California, United States
Research Site
Los Angeles, California, United States
Research Site
Oceanside, California, United States
Research Site
Pasadena, California, United States
...and 70 more locations